相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeted therapy for breast cancer in older patients
Noam Ponde et al.
JOURNAL OF GERIATRIC ONCOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER2-positive advanced breast cancer treatment in 2020
Marcelle G. Cesca et al.
CANCER TREATMENT REVIEWS (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients
Masataka Sawaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Progress in adjuvant systemic therapy for breast cancer
Noam F. Ponde et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology
Etienne Brain et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Abstract P5-21-08: Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
T O'Connor et al.
CANCER RESEARCH (2018)
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Noam Ponde et al.
CANCER TREATMENT REVIEWS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant treatment of HER2-positive early breast cancer
Alvaro Moreno-Aspitia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany
Peter Dall et al.
JOURNAL OF GERIATRIC ONCOLOGY (2015)
Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
Evandro de Azambuja et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials
Janaina Brollo et al.
CANCER TREATMENT REVIEWS (2013)
Research Priorities in Geriatric Oncology: Addressing the Needs of an Aging Population
Arti Hurria et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
Robert I. Griffiths et al.
CANCER INVESTIGATION (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
